Trevi Therapeutics announced the appointment of James Cassella, Ph.D., as Chief Development Officer. Cassella has over 35 years of experience working in publicly traded drug and product development companies with a specific focus on CNS therapies. Prior to joining Trevi, he served as Chief Development Officer for Concert Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics’ Haduvio shows cough relief efficacy in Phase 2a trial
- Trevi Therapeutics assumed with an Outperform at Leerink
- Abercrombie upgraded, Dollar General downgraded: Wall Street’s top analyst calls
- Trevi initiated with Outperform on cough potential at Raymond James
- Trevi Therapeutics initiated with an Outperform at Raymond James